Patents Examined by Rodney P Swartz
  • Patent number: 10703784
    Abstract: The present invention relates to M. tuberculosis proteins and peptides, and subsequences, portions or modifications thereof and methods and compounds comprising the same for eliciting, stimulating, inducing, promoting, increasing, or enhancing an anti-M. tuberculosis immune response in a subject.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: July 7, 2020
    Assignee: LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Alessandro Sette, Cecilia Arlehamm, Bjoern Peters, Howard Grey, John Sidney
  • Patent number: 10702563
    Abstract: Methods for inhibiting the negative metabolic and/or inflammatory impact of endurance exercise by administration of nucleotides is disclosed.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: July 7, 2020
    Assignee: NU Science Laboratories, Inc.
    Inventors: William J. Kraemer, Mark G. Connell
  • Patent number: 10702558
    Abstract: The invention relates to methods for treating or preventing abnormal skin conditions in a human in need thereof, comprising administering a cell culture composition comprising a living culture of bacteria comprising at least one engineered strain that produces a recombinant polypeptide for therapeutic treatment of the abnormal skin condition. The invention also relates to pharmaceutical compositions containing, as the active principle, engineered microorganisms expressing non-vaccinogenic pharmacologically active recombinant therapeutic polypeptides in order to treat or prevent abnormal skin conditions.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: July 7, 2020
    Assignee: Azitra Inc
    Inventors: Azim Momin Munivar, Travis Michael Whitfill
  • Patent number: 10695386
    Abstract: A system for treating and maintaining the health of the skin of a user. The system may include a topical formulation and an oral formulation. The topical formation may include various probiotic organisms selected for enhancing and treating the skin of a user. The oral formulation may include various probiotic organisms for enhancing and treating the skin of the user. The topical formulation and the oral formulation may be used cooperatively and simultaneously to produce a beneficial, synergistic effect.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: June 30, 2020
    Inventor: Shayne K. Morris
  • Patent number: 10677797
    Abstract: Provided herein is an assay for detecting a rough-type mycobacterium and a smooth-type mycobacterium in a sample, wherein the mycobacterium is Mycobacterium tuberculosis or Mycobacterium bovis. The assay comprises a first molecule that selectively binds to the rough-type mycobacterium or binds to a molecule preferentially secreted by the rough-type mycobacterium and a second molecule that selectively binds to the smooth-type mycobacterium or binds to a molecule preferentially secreted by the smooth-type mycobacterium. The first molecule and the second molecule are independently detectable. Also provided herein are corresponding methods for detecting a rough-type mycobacterium and a smooth-type mycobacterium in a sample and assays and methods for detecting tuberculosis infection in a sample.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 9, 2020
    Assignee: S&R PHARMACEUTICALS, LLC
    Inventor: Tsungda Hsu
  • Patent number: 10668136
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: June 2, 2020
    Assignee: INTREXON ACTOBIOTICS NV
    Inventors: Pieter Rottiers, Veerle Snoeck
  • Patent number: 10669316
    Abstract: The present invention relates to compositions comprising improved flagellin derived constructs and methods of using the same in the treatment of various diseases.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: June 2, 2020
    Assignee: Genome Protection, Inc.
    Inventor: Vadim Mett
  • Patent number: 10655137
    Abstract: Provided is an influenza mucosal vaccine composition and preparation and application thereof. This composition contains an antigen fusion protein which includes an influenza virus antigen and a Type IIb heat-labile enterotoxin A subunit from Escherichia coli. Immunization with this antigen fusion protein induces cellular and humoral immune responses, including systemic and mucosal immune responses, against a specific influenza virus in a subject, and therefore protects the subject from viral infection.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: May 19, 2020
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Suh-Chin Wu, Shi-Wei Lin, Neos Tang, Ting-Hsung Chen
  • Patent number: 10653764
    Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: May 19, 2020
    Assignee: Pfizer Inc.
    Inventors: David Cooper, Kathrin Ute Jansen, Michael William Pride
  • Patent number: 10646520
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of vancomycin-resistant Enterococci infection or colonization. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacteria Clostridium scindens and/or the bacteria Blautia producta contribute substantially to resistance against vancomycin-resistant Enterococci infection or colonization. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids in the case of Clostridium scindens.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 12, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Eric Pamer, Peter McKenney, Silvia Caballero
  • Patent number: 10639361
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Patent number: 10641770
    Abstract: The present invention discloses in vitro and in vivo diagnostic methods with enhanced specificity and sensitivity for the detection of tuberculosis. The diagnostic reagents of the present invention can replace former mixtures/cocktails/pools of antigens comprising ESAT-6 but including ESAT6 improves the diagnosis even further.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 5, 2020
    Assignee: Statens Serum Institut
    Inventors: Claus Aagaard, Søren Tetens Hoff, Ida Rosenkrands, Else Marie Agger, Peter Lawætz Andersen
  • Patent number: 10632158
    Abstract: Methods for treating and preventing dysbiosis in a subject suffering from or susceptible to gastrointestinal disorders are described. The methods comprises administering a hyperimmunized egg product to the subject, wherein the egg product is obtained from a hyperimmunized avian, optionally in combination with an additional compound such as a probiotic and/or nutrient source.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: April 28, 2020
    Assignee: IGY Nutrition
    Inventor: Susan J. Hewlings
  • Patent number: 10617697
    Abstract: A vitamin D2-enriched biomass of an edible fungus, extracts and compositions thereof are provided, for use in delaying onset of, treating, ameliorating or protecting from an immune-related or inflammatory related disease, disorder or condition, wherein the level of vitamin D2 in said biomass is at least 80 IU/gr.
    Type: Grant
    Filed: January 17, 2016
    Date of Patent: April 14, 2020
    Assignees: GAVISH-GALILEE BIO APPLICATIONS, LTD., HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
    Inventors: Dan Levanon, Yaron Ilan, Ofer Danai
  • Patent number: 10617730
    Abstract: The present invention relates to extracellular polysaccharide produced from Ceriporia lacerata, a mycelium culture medium of Ceriporia lacerata containing the extracellular polysaccharide, and a composition for preventing alopecia or stimulating hair growth containing dry powder or an extract of the mycelium culture medium as an active ingredient. The composition according to the present invention inhibits expression of TGF-? and is thus superb in preventing alopecia or stimulating hair growth and a composition containing said composition can be effectively used as a pharmaceutical composition, quasi-drug, healthy functional food and cosmetic composition for preventing alopecia or stimulating hair growth.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 14, 2020
    Assignee: FUGENBIO CO., LTD.
    Inventor: Yoon Soo Kim
  • Patent number: 10613084
    Abstract: Herein is provided a method that provides a patient, suspected of having Lyme disease, a kit that does not require specialized equipment and allows for easy self-collection of specimens. Methods provided herein, allow for the efficient culturing of Borrelia spirochetes, such as B. burgdorferi spirochetes after being exposed to an environment that is typically not suitable for Borrelia growth.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 7, 2020
    Inventors: Marianne Middelveen, Raphael Stricker
  • Patent number: 10610577
    Abstract: An immunomodulator is for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably includes a whole cell Mycobacterium, such as M. vaccae or M. obuense.
    Type: Grant
    Filed: December 16, 2014
    Date of Patent: April 7, 2020
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10610578
    Abstract: An immunomodulator for use in the treatment, reduction, inhibition or control of a neoplastic disease in a patient intended to undergo checkpoint inhibition therapy, simultaneously, separately or sequentially with administration of the immunomodulator. The immunomodulator preferably comprises a whole cell Mycobacterium, for example, M. vaccae or M. obuense.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: April 7, 2020
    Assignee: IMMODULON THERAPEUTICS LIMITED
    Inventors: Charles Akle, John Grange, Kevin Bilyard
  • Patent number: 10597663
    Abstract: There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, and RRSP). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: March 24, 2020
    Assignee: THE HOSPITAL FOR SICK CHILDREN
    Inventors: Roman A. Melnyk, Anick Auger, Greg Beilhartz, Berge Minassian, Seiji Sugiman-Marangos
  • Patent number: 10596226
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for treating cancer using albumin-proaerolysin prodrugs. Accordingly, in one aspect, the present invention provides prodrug compositions. In certain embodiments, a prodrug composition comprises a prostate-specific antigen (PSA)-activated pro-aerolysin (PA), wherein a PSA cleavable linker replaces the native furin cleavage site within PA; and human serum albumin (HSA) or a fragment thereof fused to the N-terminus of the PSA-activated PA.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: March 24, 2020
    Assignee: The Johns Hopkins University
    Inventors: John T. Isaacs, Samuel R. Denmeade, W. Nathaniel Brennen